CTI BioPharma Investor Relations Material
Latest events
Q4 2022
CTI BioPharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CTI BioPharma Corp
Access all reports
CTI BioPharma Corp. is a biopharmaceutical company focused on the development and commercialization of novel therapies for blood-related cancers. The company’s lead product is designed to treat patients with rare blood cancers, such as myelofibrosis. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CTIC
Country
🇺🇸 United States